-
Product Insights
Systemic Sclerosis (Scleroderma) – Drugs In Development, 2023
Global Markets Direct’s, ‘Systemic Sclerosis (Scleroderma) - Drugs In Development, 2023’, provides an overview of the Systemic Sclerosis (Scleroderma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Scleroderma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OCX-063 in Proliferative Vitreoretinopathy (PVR)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OCX-063 in Proliferative Vitreoretinopathy (PVR) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OCX-063 in Proliferative Vitreoretinopathy (PVR) Drug Details: OCX-063 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LMY-920 in Non-Hodgkin Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.LMY-920 in Non-Hodgkin Lymphoma Drug Details:LMY-920 is under development for the treatment of mantle cell lymphoma,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRJ-13024 in Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRJ-13024 in Renal Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PRJ-13024 in Renal Cell Carcinoma Drug Details:PRJ-13024 is under development for the...
-
Product Insights
Multiple Myeloma (Kahler Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Multiple Myeloma Pipeline Products Market Report Overview Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. It mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain, and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery. The Multiple Myeloma Drugs in Development market research...
-
Product Insights
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Acute lymphocytic leukemia (ALL) is a cancer of the white blood cells due to the production of a large number of immature lymphocytes thus blocking the production of normal blood cells. Risk factors for ALL include exposure to radiation or chemicals, age, virus infections, and genetic factors. Symptoms include anemia, frequent infections, easy bruising, bone pain, and breathing problems. Treatment includes chemotherapy, transfusions, transplant, and medications. The ALL pipeline drugs market research report provides comprehensive information on the therapeutics under...
-
Product Insights
Non-Hodgkin Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body’s immune system. Symptoms may include night sweats, fever and chills that come and go, itching, putting pressure on the windpipe (trachea) or other airways, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if cancer affects the brain. Treatment includes surgery,...
-
Product Insights
Systemic Sclerosis (Scleroderma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Symptoms include muscle pains, joint pain and swelling, ulcers occurring on fingertips, bloating of the tummy and diarrhea or constipation. Treatment includes antibiotic, pain relievers and immunosuppressant. Global Markets Direct’s report features investigational drugs from across globe. The Systemic Sclerosis (Scleroderma) - Drugs In Development research report provides a comprehensive overview on the therapeutics  under  development  for  Systemic  Sclerosis  (Scleroderma),  complete  ...